AKLRD’s focus is in inflammatory diseases with a high unmet need

AKLRD identifies secondary metabolites of plant origin with proven efficacy & safety, and which are capable of being synthesized. These synthetic metabolites then undergo standard pharmaceutical clinical development.

AKLRD’s innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.

AKLRD has identified two isomers which act synergistically and have been combined to create AKL4 [APPA], a patented investigational oral medicine showing great promise in the treatment of inflammatory conditions including osteoarthritis.

Having recently completed a Phase I study, a Phase 2 150-patient 28 day dosing placebo-controlled Human Efficacy Study of APPA in osteoarthritis of the knee is currently underway in Denmark. Started 4Q 2020, last patient visit early 2Q and due to report 3Q 2021.